Scholarlink

<p>Although several studies have investigated synovial sarcoma using established cell lines and mouse models, effective treatments remain limited. We treated five patients with synovial sarcoma at our institute between 2022 and 2023, and resected tumor specimens were cultured using a modified air–liquid interface organoid method. After serial passaging and xenografting into NOD-scid IL2Rgnull (NSG) mice, patient-derived organoid lines were successfully established in three of five cases. These organoids exhibited stable propagation, tumorigenicity, and retained histological and genetic features of the original tumors, including <i>SS18–SSX</i> fusion confirmed by polymerase chain reaction and Sanger sequencing. We then evaluated the organoids’ response to a ferroptosis-inducing agent previously reported to be effective in synovial sarcoma. Despite low malic enzyme 1 (<i>ME1</i>) expression, which has been associated with ferroptosis sensitivity, the established organoids were resistant to treatment. This unexpected result suggests additional mechanisms of resistance and highlights the complexity of ferroptosis regulation in synovial sarcoma. Our findings demonstrate the feasibility of establishing synovial sarcoma organoids using a modified culture method and suggest their potential as preclinical models for drug screening and mechanistic studies. These models provide a valuable resource for the development of novel therapeutic strategies for this rare and aggressive tumor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月21日

查看全文
  • Toru Wakamatsu,
  • Yoshiki Yamada,
  • Keiichi Yoshida,
  • Yukiko Matsuoka,
  • Satoru Sasagawa,
  • Noriko Nagamine,
  • Kazuko Shizuma,
  • Rie Suzuki,
  • Hironari Tamiya,
  • Yoshinori Imura,
  • Sho Nakai,
  • Seiji Okada,
  • Toshinari Yagi,
  • Ken-ichi Yoshida,
  • Shigeki Kakunaga,
  • Yoshihiro Yui,
  • Satoshi Takenaka

摘要

Although several studies have investigated synovial sarcoma using established cell lines and mouse models, effective treatments remain limited. We treated five patients with synovial sarcoma at our institute between 2022 and 2023, and resected tumor specimens were cultured using a modified air–liquid interface organoid method. After serial passaging and xenografting into NOD-scid IL2Rgnull (NSG) mice, patient-derived organoid lines were successfully established in three of five cases. These organoids exhibited stable propagation, tumorigenicity, and retained histological and genetic features of the original tumors, including SS18–SSX fusion confirmed by polymerase chain reaction and Sanger sequencing. We then evaluated the organoids’ response to a ferroptosis-inducing agent previously reported to be effective in synovial sarcoma. Despite low malic enzyme 1 (ME1) expression, which has been associated with ferroptosis sensitivity, the established organoids were resistant to treatment. This unexpected result suggests additional mechanisms of resistance and highlights the complexity of ferroptosis regulation in synovial sarcoma. Our findings demonstrate the feasibility of establishing synovial sarcoma organoids using a modified culture method and suggest their potential as preclinical models for drug screening and mechanistic studies. These models provide a valuable resource for the development of novel therapeutic strategies for this rare and aggressive tumor.